Women’s Health Dx
NEW SCIENTIFIC PUBLICATION SHOWS SERA PROGNOSTICS IS LEADER IN ASSESSING PRETERM BIRTH RISK
Nov 18, 2019 – Sera announced that a key scientific publication, “Effects of Selective Exclusion of Patients on Preterm Birth Test Performance,” authenticates Sera as the leading authority in using biomarkers to assess preterm birth risk. Read More >
SERA PROGNOSTICS RAISES $36 MILLION SERIES D FINANCING LED BY BLUE OX HEALTHCARE PARTNERS
Nov. 13, 2019 – Sera announced it has raised $36 million in Series D financing led by Blue Ox Healthcare Partners, an investment firm providing growth capital to healthcare companies targeting individuality and value-based care. Read More >
Sera Prognostics to Present at the 31st Annual Piper Jaffray Healthcare Conference
Nov. 1, 2019 -- Sera Prognostics will be presenting at the upcoming Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City on Thursday, December 5th at 12:30 p.m. ET. Read More >
Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications
Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 9.6% of pregnancies in the U.S. alone.
Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM® Test for Risk Management.